Hidden blood vessels may shield eyes from blindness, new study suggests

NCT ID NCT06125977

Ongoing Knowledge-focused Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a specific type of blood vessel growth under the retina, called non-exudative type 1 macular neovascularization (MNV), in people with age-related macular degeneration (AMD). Researchers want to see if these vessels actually help preserve vision rather than harm it. They will measure changes in retinal sensitivity and structure over time in 73 participants aged 50 and older. The goal is to challenge the current belief that all new blood vessel growth in AMD is harmful.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If this study confirms that non-exudative type 1 MNV protects vision, it could shift how doctors view and manage AMD, potentially leading to new strategies that preserve sight.
What could go wrong: This is an observational study with only 73 participants, so results may not apply to everyone. It aims to understand a phenomenon, not test a treatment, so no direct benefit is guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration choroidal neovascularization macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

University of Utah

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.